These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 33888593)
1. Icosapent ethyl: scientific and legal controversies. Curfman G; Shehada E Open Heart; 2021 Apr; 8(1):. PubMed ID: 33888593 [TBL] [Abstract][Full Text] [Related]
2. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid. Chapman MJ; Zamorano JL; Parhofer KG Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222 [TBL] [Abstract][Full Text] [Related]
3. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Ballantyne CM; N Engl J Med; 2019 Jan; 380(1):11-22. PubMed ID: 30415628 [TBL] [Abstract][Full Text] [Related]
4. Catch of the Day: Icosapent Ethyl for Reducing Cardiovascular Risk. Dixon DL Am J Med; 2020 Jul; 133(7):802-804. PubMed ID: 32243872 [TBL] [Abstract][Full Text] [Related]
5. The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention. Trivedi K; Le V; Nelson JR Postgrad Med; 2021 Jan; 133(1):28-41. PubMed ID: 32762268 [TBL] [Abstract][Full Text] [Related]
6. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides. Kedia AW; Lynch E Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247 [TBL] [Abstract][Full Text] [Related]
7. Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides. Pareek M; Mason RP; Bhatt DL Expert Opin Drug Saf; 2022 Jan; 21(1):31-42. PubMed ID: 34253137 [TBL] [Abstract][Full Text] [Related]
8. Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis. Brinton EA; Ballantyne CM; Guyton JR; Philip S; Doyle RT; Juliano RA; Mosca L J Womens Health (Larchmt); 2018 Sep; 27(9):1170-1176. PubMed ID: 29583081 [TBL] [Abstract][Full Text] [Related]
9. Icosapent Ethyl for Primary Versus Secondary Prevention of Major Adverse Cardiovascular Events in Hypertriglyceridemia: Value for Money Analysis. Arbel R; Aboalhasan E; Hammerman A; Azuri J Am J Med; 2021 Jul; 134(7):e415-e419. PubMed ID: 33450273 [TBL] [Abstract][Full Text] [Related]
10. Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol. Bazarbashi N; Miller M Expert Rev Cardiovasc Ther; 2020 Apr; 18(4):175-180. PubMed ID: 32228246 [TBL] [Abstract][Full Text] [Related]
11. Reduction of cardiovascular risk with icosapent ethyl (Vascepa). Med Lett Drugs Ther; 2020 Feb; 62(1591):17-18. PubMed ID: 32022786 [No Abstract] [Full Text] [Related]
12. Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study. Budoff M; Brent Muhlestein J; Le VT; May HT; Roy S; Nelson JR Clin Cardiol; 2018 Jan; 41(1):13-19. PubMed ID: 29365351 [TBL] [Abstract][Full Text] [Related]
13. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies. Ballantyne CM; Bays HE; Philip S; Doyle RT; Braeckman RA; Stirtan WG; Soni PN; Juliano RA Atherosclerosis; 2016 Oct; 253():81-87. PubMed ID: 27596132 [TBL] [Abstract][Full Text] [Related]
14. Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction. Boden WE; Baum S; Toth PP; Fazio S; Bhatt DL Future Cardiol; 2021 Jan; 17(1):155-174. PubMed ID: 32959713 [TBL] [Abstract][Full Text] [Related]
15. Reducing Cardiovascular Disease Risk in Women Beyond Statin Therapy: New Insights 2020. Mosca L; Navar AM; Wenger NK J Womens Health (Larchmt); 2020 Aug; 29(8):1091-1100. PubMed ID: 32297837 [TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of omega-3 polyunsaturated fatty acids - The Australian healthcare perspective. Gao L; Moodie M; Li SC Eur J Intern Med; 2019 Sep; 67():70-76. PubMed ID: 31285124 [TBL] [Abstract][Full Text] [Related]
17. Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients. Crandell JR; Tartaglia C; Tartaglia J Postgrad Med; 2016 Nov; 128(8):859-864. PubMed ID: 27684412 [TBL] [Abstract][Full Text] [Related]